The Effect of Aspirin on Recurrent Acute Pancreatitis

Launched by AIR FORCE MILITARY MEDICAL UNIVERSITY, CHINA · Dec 15, 2023

Keywords

ClinConnect Summary

This clinical trial is studying whether taking 100 mg of aspirin can help prevent recurrent acute pancreatitis, which is when a person has two or more episodes of sudden inflammation of the pancreas. This condition can make patients feel very unwell and can lead to other health issues, so finding effective ways to prevent it is important. The trial is open to individuals aged 51 to 92 who have experienced recurrent acute pancreatitis. However, those who have had fewer than two episodes in the past year or have certain medical conditions, like recent surgery or ongoing health issues, will not be eligible to participate.

If you qualify and choose to join the trial, you will be asked to take aspirin regularly and will be monitored to see if this helps reduce the chances of future pancreatitis attacks. This study is currently recruiting participants, and it aims to explore a potential new way to help people manage their condition better. If you have any questions or want more information, please feel free to reach out!

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with with recurrent acute pancreatitis
• Exclusion Criteria:
• • Less than 2 episodes of acute pancreatitis in the past year
• • Latrogenic AP (pancreatitis due to endoscopic retrograde cholangiopancreatography, surgery, or after other invasive treatment). Iatrogenic pancreatitis will not count as an episode of recurrent pancreatitis
• • Previous allergy to Non-Steroid Anti-inflammatory Drugs (NSAIDs)
• • Regularly taking aspirin or other NSAIDs \>3 doses per week
• • Contradictions for the medications of NSAIDs, including Active peptic ulcer disease or gastrointestinal hemorrhage within 3 months or previous peptic ulcer, history of significant hepatic or renal disease, platelet count less than 100X10\^9/L or international normalized ratio (INR) \>1.5)
• • Biliary stones
• • Receiving endoscopic sphincterotomy and/or pancreatic stent placement and/or cholecystectomy and/or pancreatic surgery after the latest pancreatitis or planning to undergo one of those interventions within preceding 2 years
• • Patients with the level of serum triglycerides of \>5.65 mmol/L and did not receive regular lipid-lowering therapy
• • Primary hyperparathyroidism has been well-treated after last episode of pancreatitis and recruitment or will be operated in \<2 years
• • Patients with previously heavy alcohol consumption (50g/day for men, 40g/day for women) and have not quit drinking, or have significant withdrawal symptoms
• • Pregnant or breastfeeding patients
• • Inability to give informed consents